Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Long-Term Deferred Tax: 2014-2020

Historic Long-Term Deferred Tax for Enanta Pharmaceuticals (ENTA) over the last 7 years, with Sep 2020 value amounting to $345,000.

  • Enanta Pharmaceuticals' Long-Term Deferred Tax fell 97.74% to $345,000 in Q2 2021 from the same period last year, while for Jun 2021 it was $345,000, marking a year-over-year decrease of 97.74%. This contributed to the annual value of $345,000 for FY2020, which is 96.96% down from last year.
  • As of FY2020, Enanta Pharmaceuticals' Long-Term Deferred Tax stood at $345,000, which was down 96.96% from $11.3 million recorded in FY2019.
  • Over the past 5 years, Enanta Pharmaceuticals' Long-Term Deferred Tax peaked at $11.3 million during FY2019, and registered a low of $345,000 during FY2020.
  • For the 3-year period, Enanta Pharmaceuticals' Long-Term Deferred Tax averaged around $6.7 million, with its median value being $8.4 million (2018).
  • Per our database at Business Quant, Enanta Pharmaceuticals' Long-Term Deferred Tax surged by 80.82% in 2016 and then slumped by 96.96% in 2020.
  • Over the past 5 years, Enanta Pharmaceuticals' Long-Term Deferred Tax (Yearly) stood at $8.4 million in 2016, then climbed by 20.66% to $10.1 million in 2017, then decreased by 17.27% to $8.4 million in 2018, then soared by 35.41% to $11.3 million in 2019, then slumped by 96.96% to $345,000 in 2020.